Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for hodgkin lymphoma patients who Can't have transplants

NCT ID NCT06393361

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated Apr 24, 2026 · Updated 19 times

Summary

This study tests a new combination of drugs (Chidamide, Decitabine, and an anti-PD-1 antibody) for people with classical Hodgkin lymphoma that has come back or not responded to treatment, and who cannot or choose not to have a stem cell transplant. The goal is to see if this combination helps control the cancer longer than another standard treatment. About 100 adults aged 18-75 will participate, and the main focus is on how long they live without the cancer getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INELIGIBLE OR REFUSED TRANSPLANT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Biotherapeutic Department and Hematology Department of Chinese PLA General Hospital

    RECRUITING

    Beijing, 100853, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

INELIGIBLE OR REFUSED TRANSPLANT PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA